stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) Debt to equity
PTC Therapeutics, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was −14.9×, down 2.2× from fiscal 2025 (−12.7×). Over the past ten years it has ranged from −12.7× (fiscal 2025) to 824× (fiscal 2021) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 0.0× and below the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | −12.7× | — |
| FY2024 | −2.2× | — |
| FY2023 | −2.6× | — |
| FY2022 | −3.9× | — |
| FY2021 | 824× | 39,164.12% |
| FY2020 | 2.1× | 297.58% |
| FY2019 | 0.5× | 21.04% |
| FY2018 | 0.4× | (52.92%) |
| FY2017 | 0.9× | 12.83% |
| FY2016 | 0.8× | 102.09% |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | −14.9× | — |
| Jun 2026 | −17.6× | — |
| Mar 2026 | −14.5× | — |
| Dec 2025 | −12.7× | — |
| 43 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| PTCT PTC Therapeutics, Inc. | −14.9× |
| MIRM Mirum Pharmaceuticals, Inc. compare | −13.5× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.0× |
| MANE Veradermics Incorporated compare | 0.0× |
| IMVT Immunovant, Inc. compare | 0.0× |
| KOD Kodiak Sciences Inc. compare | 0.0× |
| CGON CG Oncology, Inc. compare | 0.0× |
| COGT Cogent Biosciences, Inc. compare | 0.4× |
| SRRK Scholar Rock Holding Corporation compare | 0.8× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on PTCT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement